NCT01245179View on ClinicalTrials.gov

Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Sickle Cell Disease
Interventions
DRUG

panobinostat

"Panobinostat oral capsules taken THRICE WEEKLY (Monday, Wednesday, and Friday) for 12 weeks, exploring the following dosing regimens:~1. 15 mg MWF 3 weeks on, 1 week off (if needed)~2. 15 mg MWF every week (starting dose)~3. 20 mg MWF 3 weeks on, 1 week off~4. 20 mg MWF every week"

Trial Locations (1)

30912

RECRUITING

Augusta University, Augusta

All Listed Sponsors
collaborator

Secura Bio, Inc.

INDUSTRY

lead

Abdullah Kutlar

OTHER